Kite Pharma, Inc. (KITE) managed to eke out gains of 1.57% in intraday trade. The share price increased by 1.31 points to $84.87. Till last observation, the net money flow was recorded at a negative $(-1.62) million. The total inflow of $14.13 million in upticks was completely overshadowed by an outflow of $15.75 million in downticks, giving the up/down ratio a value of 0.9. The shares have seen a change of 1.06% in the past week.A block trade occurred in the company shares in which the composite value of the upticks was $0 million and the composite value in downticks was $2.61 million. The resultant up/down ratio for the block exchange was 0. The block trade had a negative money flow of $(-2.61) million.
Based on the Stock Research reports from financial advisors, there are 8 Analysts recommending as a Strong Buy, and 2 Analysts recommending as a Moderate Buy. Investors should also note that 4 Stock brokerage firms are recommending to Hold the stock for short term. Kite Pharma, Inc. (NASDAQ:KITE) rose 0.95% or 0.79 points on Thursday and made its way into the gainers of the day. After trading began at $83.31 the stock was seen hitting $85.74 as a peak level and $82.6 as the lowest level. The stock ended up at $84.35. The daily volume was measured at 1,348,169 shares. The 52-week high of the share price is $88.58 and the 52-week low is $39.82. The company has a market cap of $4,694 million.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.